Skip to content Skip to footer
Subscribe Now
Insights+: EMA Marketing Authorization of New Drugs in December 2023
INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in December 2023

Shots: The EMA approved 3 BLA while 4 New Chemical Entities in December 2023, leading to treatments for patients and advances in the healthcare industryIn December 2023, the major highlighted drugs were Jempreli to treat dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer and Zilbrysq for the treatment of Generalized Myasthenia Gravis  PharmaShots has compiled a list of a…
January 23, 2024

Read more

Exclusive_Noelle Bush_2024
EXCLUSIVE

Noelle Bush in an Enlightening Interview with PharmaShots Shares Insights from the It Takes 2 Awareness Program

Shots: Exemplifying awareness campaign at its best with a hint of contemporary music, “It takes 2” by Boehringer Ingelheim and Eli Lilly is a noble initiative aimed at integrating UACR testing with eGFR for better screening of CKD Noelle Bush, in an engaging conversation with PharmaShots, cites the growing incidences of CKD in the US.…
January 15, 2024

Read more

VIEWPOINTS_Mohamed Eid_2023
VIEWPOINTS

Unlocking Approval: Mohamed Eid Dives into the Exciting Approval of Jardiance for Adult CKD Treatment in a Captivating Chat with PharmaShots

Shots: Mohamed Eid, VP of Clinical Development & Medical Affairs, Cardio-Renal-Metabolism & Respiratory Medicine, at Boehringer Ingelheim, in a stimulating conversation with PharmaShots sheds light on the recent approval of Jardiance for the treatment of adults with chronic kidney disease  Jardiance’s EMPA Kidney P-III trial results demonstrated a 28% relative risk reduction vs placebo. Jardiance…
December 5, 2023

Read more

Spending on R&D Top 20 2022
TOP 20

Top 20 Companies Spending on R&D in 2022

Shots:R&D (Research and Development) in the biopharma industry lays the foundation stone of innovative drugs. A robust R&D bolstered with new-age technological advances assures long-term sustainability in the future marketWith a global expenditure of $238B in 2022, the figures are anticipated to reach $285B by 2028. In 2022, AbbVie ranked the top among…
August 22, 2023

Read more

Companies Spending on R&D Top 20 2022
TOP 20

Top 20 Companies Spending on R&D in 2022

Shots:R&D (Research and Development) in the biopharma industry lays the foundation stone of innovative drugs. A robust R&D bolstered with new-age technological advances assures long-term sustainability in the future marketWith a global expenditure of $238B in 2022, the figures are anticipated to reach $285B by 2028. In 2022, AbbVie ranked the top among…
August 22, 2023

Read more

Load more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]